Data Gaps that Bottleneck Aging Biomarker Discovery — Norn Group
What’s holding back aging biomarkers? Despite growing excitement, most aging biomarkers today remain clinically irrelevant. This piece dives into the real bottleneck: our data. It maps the missing datasets, outlines what’s actually needed for biomarker validation, and proposes a path forward—design
By Marton Meszaros Developing “aging clocks” or “biomarkers of aging” is a popular pursuit within the aging research community, and increasingly also in popular culture. We now have dozens of unverified consumer tests, hundreds of papers worth of research for research’s sake, and some good work that may lead somewhere. The impact of all the work on aging biomarkers today - on clinical care, or on improving the development of therapeutics - is far below what promises to be, and what it could be. In this piece, I make the claim that aging biomarker discovery is bottlenecked in large part by…
saved by
related reading
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Gap Mapgap-map.org
- What the Aging Field Needs - Celine Haliouacelinehh.com
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Anti-Aging: State of the Art — LessWronglesswrong.com
- Longevity FAQ - Laura Demingldeming.com
- The Hallmarks of Agingncbi.nlm.nih.gov
- Nintil - From chaos, order: On the nature and measurement of biological agingnintil.com
- Nintil - The Longevity FAQnintil.com
- A primer on the current state of longevity researchowlposting.com
- The “Stepping Stone” Approach to Getting Longevity Drugs to Market - proto.lifeproto.life
- The Longevity Land Grab | Will Ventureswillventures.com